Colchicine is a medication most commonly used in the treatment of gout and familial mediterannean fever. A rare complication of therapy is toxicity causing proximal myopathy and polyneuropathy. Colchicine myopathy has been associated with the coadministration of other medications with colchicine, such as statins or tacrolimus, and is more common in patients with renal impairment. Otherwise, it is unclear which patients are at greatest risk of developing this adverse drug reaction. is important to the metabolism of colchicine, so we speculated that it was possible that colchicine myopathy patients may have a particular genotype that is associated with this side effect. We describe two cases of colchicine myopathy which occurred with co-administration of rosuvastatin. From one case, we present the first published data on muscle MRI in this condition. We additionally present an analysis of four genetic polymorphisms in and transcript levels in muscle tissue, and demonstrate the descriptive finding of reduced transcript levels in the colchicine myopathy patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542945 | PMC |
| http://dx.doi.org/10.3389/fneur.2019.00553 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Colchicine Alleviates Interstitial Lung Disease in an Experimental Autoimmune Myositis Murine Model by Inhibiting the Formation of Neutrophil Extracellular Traps.
Inflammation
December 2024
Department of Rheumatology and Immunology, the Second Hospital of Lanzhou University, Lanzhou, 730030, Gansu, China.
Our previous study has shown that neutrophil extracellular traps (NETs) were associated with idiopathic inflammatory myopathy-related interstitial lung disease (IIM-ILD). Colchicine plays an anti-inflammatory role mainly by inhibiting the activity and chemotaxis of neutrophils. This study aims to verify therapeutic effects and mechanism of colchicine in IIM-ILD.
View Article and Find Full Text PDFMuscular toxicity of colchicine combined with statins: a real-world study based on the FDA adverse event reporting system database from 2004-2023.
Front Pharmacol
July 2024
Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China.
Background: Through an analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS), we explored the signal strength of adverse reactions (ADRs) related to myopathy caused by the combination of colchicine and statins and gained insight into the characteristics of these myopathy related ADRs.
Methods: We extracted data from the FAERS database about ADRs in individuals with myopathy resulting from the combination of colchicine and statins. The analysis was conducted for the period spanning from January 2004 to December 2023 using the reported odds ratio (ROR) and information component (IC) methods to assess muscle-related ADR signals.
Effectiveness of Mesotherapy in Post-COVID Pain Syndrome: Retrospective Cohort Study of 96 Patients.
Clin Ther
August 2024
Çukurova State Hospital, Physical Medicine and Rehabilitation Clinic, Adana, Turkey.
Article Synopsis
- This study investigates the effectiveness of mesotherapy in managing chronic musculoskeletal pain following COVID-19 infection in 96 patients.
- Two treatment groups were analyzed: one receiving oral medications (diclofenac potassium, thiocolchicoside, cyanocobalamin) and the other undergoing intradermal mesotherapy using lidocaine and cyanocobalamin.
- Results showed that both treatments improved pain and neuropathic symptoms, but mesotherapy proved significantly more effective than oral therapy, with greater reductions in pain scores.
Risk for cancer development in familial Mediterranean fever and associated predisposing factors: an ambidirectional cohort study from the international AIDA Network registries.
Front Immunol
May 2024
Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Siena, Italy.
Article Synopsis
- The study investigates the relationship between Familial Mediterranean fever (FMF), a severe inflammatory condition, and the risk of cancer development compared to other diseases like fibromyalgia, Still's disease, and Behçet's disease.
- Results show that FMF patients have a significantly lower risk for malignancies compared to fibromyalgia patients, with a risk ratio (RR) of 0.26; however, this risk is less clear when comparing with the other conditions.
- Factors influencing cancer risk in FMF patients include age at onset and diagnosis, frequency of disease attacks, and treatment with specific biotechnological agents.
Drug-Induced Myopathies: A Comprehensive Review and Update.
Biomedicines
April 2024
Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland.
Drug-induced myopathies are a common cause of muscle pain, and the range of drugs that can cause muscle side effects is constantly expanding. In this article, the authors comprehensively discuss the diagnostic and therapeutic process in patients with myalgia, and present the spectrum of drug-induced myopathies. The review provides a detailed analysis of the literature on the incidence of myopathy during treatment with hypolipemic drugs, beta-blockers, amiodarone, colchicine, glucocorticosteroids, antimalarials, cyclosporine, zidovudine, and checkpoint inhibitors, a group of drugs increasingly used in the treatment of malignancies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!